Elisabeth R van Wering
Overview
Explore the profile of Elisabeth R van Wering including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
913
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westers T, van der Velden V, Alhan C, Bekkema R, Bijkerk A, Brooimans R, et al.
Leuk Res
. 2011 Oct;
36(4):422-30.
PMID: 21982641
Flow cytometry (FC) is recognized as an important tool in the diagnosis of myelodysplastic syndromes (MDS) especially when standard criteria fail. A working group within the Dutch Society of Cytometry...
2.
Balgobind B, van den Heuvel-Eibrink M, de Menezes R, Reinhardt D, Hollink I, Arentsen-Peters S, et al.
Haematologica
. 2010 Oct;
96(2):221-30.
PMID: 20971820
Background: Pediatric acute myeloid leukemia is a heterogeneous disease characterized by non-random genetic aberrations related to outcome. The genetic subtype is currently detected by different diagnostic procedures which differ in...
3.
Gohring G, Michalova K, Beverloo H, Betts D, Harbott J, Haas O, et al.
Blood
. 2010 Aug;
116(19):3766-9.
PMID: 20802024
To identify cytogenetic risk factors predicting outcome in children with advanced myelodysplastic syndrome, overall survival of 192 children prospectively enrolled in European Working Group of Myelodysplastic Syndrome in Childhood studies...
4.
Balgobind B, Hollink I, Reinhardt D, van Wering E, De Graaf S, Baruchel A, et al.
Eur J Cancer
. 2010 Mar;
46(10):1892-9.
PMID: 20233657
Mixed-lineage leukaemia (MLL)-partial tandem duplications (PTDs) are found in 3-5% of adult acute myeloid leukaemia (AML), and are associated with poor prognosis. In adult AML, MLL-PTD is only detected in...
5.
Bateman C, Colman S, Chaplin T, Young B, Eden T, Bhakta M, et al.
Blood
. 2010 Jan;
115(17):3553-8.
PMID: 20061556
Chimeric fusion genes are highly prevalent in childhood acute lymphoblastic leukemia (ALL) and are mostly prenatal, early genetic events in the evolutionary trajectory of this cancer. ETV6-RUNX1-positive ALL also has...
6.
Veerman A, Kamps W, van den Berg H, van den Berg E, Bokkerink J, Bruin M, et al.
Lancet Oncol
. 2009 Sep;
10(10):957-66.
PMID: 19747876
Background: A population-based cohort of children aged 1-18 years with acute lymphoblastic leukaemia (ALL) was treated with a dexamethasone-based protocol (Dutch Childhood Oncology Group [DCOG] ALL-9). We aimed to confirm...
7.
van Grotel M, van den Heuvel-Eibrink M, van Wering E, van Noesel M, Kamps W, Veerman A, et al.
Pediatr Blood Cancer
. 2008 Aug;
51(6):737-40.
PMID: 18683236
Background: Children with T-lineage acute lymphoblastic leukemia (T-ALL) have an inferior outcome with combination chemotherapy compared to B-lineage ALL, and still about 30% of the patients relapse within the first...
8.
Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo H, van der Spek P, et al.
Blood
. 2008 Feb;
111(9):4668-80.
PMID: 18299449
T-cell acute lymphoblastic leukemia (T-ALL) is mostly characterized by specific chromosomal abnormalities, some occurring in a mutually exclusive manner that possibly delineate specific T-ALL subgroups. One subgroup, including MLL-rearranged, CALM-AF10...
9.
Balgobind B, Van Vlierberghe P, van den Ouweland A, Beverloo H, Terlouw-Kromosoeto J, van Wering E, et al.
Blood
. 2008 Jan;
111(8):4322-8.
PMID: 18172006
Neurofibromatosis type 1 (NF1) is an autosomal dominant genetic disorder caused by mutations in the NF1 gene. Patients with NF1 have a higher risk to develop juvenile myelomonocytic leukemia (JMML)...
10.
de Vries A, Stam R, Schneider P, Niemeyer C, van Wering E, Haas O, et al.
Haematologica
. 2007 Nov;
92(11):1557-60.
PMID: 18024405
FLT3 gene mutations have been identified as prognostic factors in myeloid malignancies. Furthermore, FLT3 can be activated by wild type overexpression or ligand-dependent in leukemic cells co-expressing FLT3 ligand (FLT3L)....